FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII

• Published in: Blood Vol. 129; no. 2; pp. 238 - 245
• Main Authors: Yoon, Jeongheon, Schmidt, Anja, Zhang, Ai-Hong, Königs, Christoph, Kim, Yong Chan, Scott, David W.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 12.01.2017; American Society of Hematology
• Subjects: Animals; B-Lymphocytes; Cell Engineering - methods; Factor VIII - immunology; Flow Cytometry; Humans; Immunosuppression - methods; Lymphocyte Activation - immunology; Mice; Mice, Knockout; Receptors, Antigen, T-Cell - immunology; T-Lymphocytes, Regulatory - immunology; Thrombosis and Hemostasis; Transduction, Genetic

Replacement therapy with factor VIII (FVIII) is used in patients with hemophilia A for treatment of bleeding episodes or for prophylaxis. A common and serious problem with this therapy is the patient's immune response to FVIII, because of a lack of tolerance, leading to the formation of inhibit...